I don't have a gripe with anyone who thinks differently, but if results are simply posted on CT and Amarin makes no mention of it, then I see no more than a buck or two of movement in sp. if Amarin announces the results AND what plans they have to bring the drug to patients within that indication, we could see much, much healthier gains. I am ignorant in this but I am assuming they would need EU approval for the indication and then those dreaded reimbursement decisions. With no DTC advertising there.
Market Data 
Markets 
AI
